Home News Healthcare

iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil

The Edge Singapore
The Edge Singapore 11/24/2021 10:17 AM GMT+08  • 2 min read
iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil
iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Pharmaceuticals company iX Biopharma has signed an exclusive license agreement with Seelos Therapeutics for its product, Wafermine.

Under terms of the agreement, iX Biopharma will receive an upfront payment of US$9 million ($12 million) to be satisfied in cash and shares.

iX Biopharma is also eligible for up to US$239 million in milestone payments upon achievement by Seelos of certain development milestones and product sales thresholds.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.